Abstract
Background
There are conflicting data in the literature about the clinical significance of aspirin resistance.
Hypothesis
We aimed to prospectively evaluate the prevalence of biochemical aspirin resistance in patients on aspirin therapy who were admitted to the emergency clinic with chest pain. We also aimed to evaluate the relation between acute coronary syndromes (ACS) and aspirin resistance.
Methods
A total of 338 patients were included in the study. Platelet reactivity was measured with the PFA‐100 system (Dade Behring Inc, Deerfield, IL). Aspirin resistance determined by the PFA‐100 was defined as a normal collagen and/or epinephrine closure time despite aspirin treatment (<165 s).
Results
Patients were divided into 4 groups: stable angina pectoris (SAP), unstable angina/non‐ST‐elevation myocardial infarction (UA/NSTEMI), ST‐elevation myocardial infarction (STEMI), and rule out ACS. Aspirin resistance was found in 81 (24%) patients in all groups. Patients with ACS had significantly more aspirin resistance than patients with rule out ACS or patients with SAP (P < .001). In the SAP group, 31 (19.6%) patients; in the UA/NSTEMI group, 19 (35.8%) patients; in the STEMI group, 14 (50%) patients; and in the rule out ACS group, 17 (17.2%) patients had aspirin resistance (P < .001). In the multivariate analysis, cardiac biomarker elevation on admission to emergency department and platelet count appeared as independent factors predictive of aspirin resistance.
Conclusions
We demonstrated that incidence of aspirin resistance was significantly higher in patients who were finally diagnosed as ACS, especially in aspirin‐taking patients admitted to the emergency clinic with STEMI. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (408.8 KB).
References
- 1.Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129–135. [DOI] [PubMed] [Google Scholar]
- 2.Antithrombotic Trialists' Collaboration. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptoknase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360. [PubMed] [Google Scholar]
- 4. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non‐ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–842. [DOI] [PubMed] [Google Scholar]
- 5. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227–1234. [DOI] [PubMed] [Google Scholar]
- 6. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705–1709. [DOI] [PubMed] [Google Scholar]
- 7. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90: 893–895. [DOI] [PubMed] [Google Scholar]
- 8. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175–181. [DOI] [PubMed] [Google Scholar]
- 9. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta‐analysis. BMJ 2008; 336: 195–198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38: 2114–2130. [DOI] [PubMed] [Google Scholar]
- 11. Poulsen TS, Jørgensen B, Korsholm L, Bjørn Licht P, Haghfelt T, Mickley H. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007; 119: 555–562. [DOI] [PubMed] [Google Scholar]
- 12. Hobikoglu GF, Norgaz T, Aksu H, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005; 207: 59–64. [DOI] [PubMed] [Google Scholar]
- 13. Tran HA, Anand SS, Hankey GJ, Eikelboom JW. Aspirin resistance. Thromb Res 2007; 120: 337–346. [DOI] [PubMed] [Google Scholar]